XML 36 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment expenses reviewed by the CDMO | The following table provides R&D expenses by program with a reconciliation to net loss for the periods indicated, which are regularly reviewed by the CODM:
| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
| (in thousands) |  |  |  |
Program expenses: |  |  |  |  |  |  |  |  |  |  |
Mecbotamab vedotin, BA3011 (CAB AXL-ADC) | $ | 3,051 |  |  | $ | 3,500 |  |  | $ | 5,992 |  |  | $ | 8,833 |
Ozuriftamab vedotin, BA3021 (CAB ROR2-ADC) |  | 1,208 |  |  |  | 2,023 |  |  |  | 3,285 |  |  |  | 4,564 |
Evalstotug, BA3071 (CAB CTLA-4) |  | 3,045 |  |  |  | 2,447 |  |  |  | 3,224 |  |  |  | 5,055 |
BA3182 (CAB EpCAM x CAB CD3) |  | 2,136 |  |  |  | 1,206 |  |  |  | 3,076 |  |  |  | 2,377 |
Other CAB Programs |  | 728 |  |  |  | 1,629 |  |  |  | 1,799 |  |  |  | 3,258 |
Total program expenses |  | 10,168 |  |  |  | 10,805 |  |  |  | 17,376 |  |  |  | 24,087 |
Personnel and related |  | 2,145 |  |  |  | 3,347 |  |  |  | 5,603 |  |  |  | 6,770 |
Equity-based compensation |  | 567 |  |  |  | 1,164 |  |  |  | 1,342 |  |  |  | 2,244 |
Facilities and other |  | 804 |  |  |  | 882 |  |  |  | 1,718 |  |  |  | 1,949 |
Total research and development expenses |  | 13,684 |  |  |  | 16,198 |  |  |  | 26,039 |  |  |  | 35,050 |
General and administrative expenses |  |  |  |  |  |  |  |  |  |  |
Personnel and related |  | 1,577 |  |  |  | 1,938 |  |  |  | 3,680 |  |  |  | 3,906 |
Equity-based compensation |  | 810 |  |  |  | 1,332 |  |  |  | 1,680 |  |  |  | 2,553 |
Facilities and other |  | 2,576 |  |  |  | 2,504 |  |  |  | 4,862 |  |  |  | 4,920 |
Total general and administrative expenses |  | 4,963 |  |  |  | 5,774 |  |  |  | 10,222 |  |  |  | 11,379 |
Interest and other income (loss) |  | (64 | ) |  |  | 900 |  |  |  | 2,216 |  |  |  | 2,123 |
Net loss and comprehensive loss | $ | (18,711 | ) |  | $ | (21,072 | ) |  | $ | (34,045 | ) |  | $ | (44,306 | )

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration